Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Surgery Partners (SGRY) Long-Term Deferred Tax (2016 - 2024)

Surgery Partners' Long-Term Deferred Tax history spans 10 years, with the latest figure at $79.2 million for Q3 2024.

  • For Q3 2024, Long-Term Deferred Tax fell 24.57% year-over-year to $79.2 million; the TTM value through Sep 2024 reached $79.2 million, down 24.57%, while the annual FY2023 figure was $89.5 million, 2.19% down from the prior year.
  • Long-Term Deferred Tax for Q3 2024 was $79.2 million at Surgery Partners, down from $81.8 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $129.8 million in Q2 2021 and bottomed at $79.2 million in Q3 2024.
  • The 5-year median for Long-Term Deferred Tax is $105.7 million (2023), against an average of $106.3 million.
  • The largest annual shift saw Long-Term Deferred Tax increased 26.44% in 2020 before it dropped 24.57% in 2024.
  • A 5-year view of Long-Term Deferred Tax shows it stood at $124.8 million in 2020, then decreased by 8.33% to $114.4 million in 2021, then dropped by 20.02% to $91.5 million in 2022, then dropped by 2.19% to $89.5 million in 2023, then fell by 11.51% to $79.2 million in 2024.
  • Per Business Quant, the three most recent readings for SGRY's Long-Term Deferred Tax are $79.2 million (Q3 2024), $81.8 million (Q2 2024), and $87.0 million (Q1 2024).